SOUTH SAN FRANCISCO, Calif. / Aug 26, 2024 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it has been named a Bay Area Top Workplace by the San Francisco Chronicle. The award marks the 11th consecutive year that Veracyte has received this honor.
The Bay Area Top Workplace award winners are determined based solely on employee feedback gathered by Energage, an employee engagement technology partner. The firm administers a confidential survey that measures employee experience and its component themes, including the degree to which employees feel respected and supported, enabled to grow and empowered to execute, among others.
“We are deeply honored to be recognized as a Top Workplace, which underscores our commitment to our employees and to our vision of transforming cancer care for patients all over the world,” said Marc Stapley, Veracyte’s chief executive officer. “At Veracyte we believe that our employees are our greatest asset and that each plays a key role in our work to guide clinicians to the right next steps for their patients, while we collectively focus on building what’s next in cancer care.”
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com and follow the company on X (formerly Twitter) at @veracyte.
Last Trade: | US$34.75 |
Daily Change: | -1.35 -3.74 |
Daily Volume: | 829,117 |
Market Cap: | US$2.730B |
September 28, 2025 September 24, 2025 September 09, 2025 August 26, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load